Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pneumococcal

- PMLiVE

Mix-and-match COVID-19 vaccines may be more effective

A small study shows a booster shot of J&J’s vaccine six months after a primary course of the Pfizer/BioNTech vaccine may offer more protection

- PMLiVE

Annual COVID-19 jabs likely, says Pfizer head

Pfizer CEO predicts annual jabs will be needed to maintain a ‘very high level of protection’ against COVID-19 and emphasises the need to vaccinate children

- PMLiVE

COVID-19 vaccines against Omicron may be fast-tracked

Regulators including the Food and Drug Administration (FDA) may treat Omicron-specific mRNA vaccines like seasonal flu vaccines, speeding up approval

regeneron headquarters

Regeneron signs $900m cancer and infectious disease deal with Nykode

The deal with Norwegian clinical-stage vaccine specialist Nykode (previously Vaccibody) includes an upfront payment of $30m and an equity investment of $20m plus additional payments

- PMLiVE

US FDA expands COVID-19 booster jabs to all adults

All Americans 18 and over are now eligible to receive a booster shot of either the Pfizer/BioNTech or Moderna COVID-19 vaccines

- PMLiVE

US government to pay $5.3bn for Pfizer‘s Paxlovid

If approved by the FDA, the US government will purchase 10 million courses of Pfizer’s anti-COVID protease inhibitor antiviral therapy, Paxlovid, this year and into 2022

- PMLiVE

Pfizer snaps up Biohaven’s migraine drug for $1.24bn

Pfizer will sell the migraine drug outside the US and will also gain the rights to a second drug

- PMLiVE

Pfizer’s oral antiviral Paxlovid significantly cuts risk of severe COVID-19

Pfizer has halted its phase 2/3 trial of its new antiviral combo Paxlovid after analysis shows it cuts the risk of hospitalisation or death from COVID-19 by nearly 90%

- PMLiVE

Pfizer’s 2021 revenue predictions soar to $82bn

Strong third-quarter revenues of $24.1bn lifted by sales of its BioNTech-partnered COVID-19 vaccine Comirnaty see Pfizer raise its 2021 revenue guidance to $82bn

- PMLiVE

Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19

Results from the world’s first randomised, controlled COVID-19 vaccine booster trial show a third dose of Pfizer-BioNTech’s Comirnaty offers near-total protection from infection

- PMLiVE

The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines

J&J’s data showed that a second shot of its vaccine boosts protection to 94% against symptomatic moderate-to-severe infection when administered two months after the first dose

- PMLiVE

Positive data for Lyme disease booster vaccine

A booster shot of Valneva/Pfizer’s VLA15 vaccine candidate against tick-borne Lyme disease demonstrates a strong immune response

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links